Intelligence Feed event · Equity · 2026-09-21

    Ionis slides over 40% year-to-date following late-stage clinical setbacks

    Question

    Ionis slides over 40% year-to-date following late-stage clinical setbacks

    Direct answer

    Ionis Pharmaceuticals shares have experienced severe multiple contraction, shedding over 40% year-to-date as clinical challenges in high-profile programs such as pelacarsen and eplontersen weighed on near-term commercialization forecasts. Despite ongoing quarterly losses, sell-side price targets average $83.82, creating an extreme divergence between prevailing market prices and fundamental platform net present value estimates.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-21
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Ionis slides over 40% year-to-date following late-stage clinical setbacks”, revision 1, evidence through 2026-09-21. https://marketontology.com/market-events/2026-09-21/ionis-slides-over-40-year-to-date-following-late-stage-clinical-setbacks-8ca437

    EQUITY
    Ionis slides over 40% year-to-date following late-stage clinical setbacks
    Ionis Pharmaceuticals shares have experienced severe multiple contraction, shedding over 40% year-to-date as clinical challenges in high-profile programs such as pelacarsen and eplontersen weighed on near-term commercialization forecasts. Despite ongoing quarterly losses, sell-side price targets average $83.82, creating an extreme divergence between prevailing market prices and fundamental platform net present value estimates.
    IONSAZN
    Impact
    65
    SEP 21
    SIG
    82%
    IONSAZN
    Ionis slides over 40% year-to-date following late-stage clinical setbacks
    Ionis Pharmaceuticals shares have experienced severe multiple contraction, shedding over 40% year-to-date as clinical challenges in high-profile programs such as pelacarsen and eplontersen weighed on near-term commercialization forecasts. Despite ongoing quarterly losses, sell-side price targets average $83.82, creating an extreme divergence between prevailing market prices and fundamental platform net present value estimates.
    → Clinical trial setbacks in pelacarsen compress Ionis commercial pipeline enterprise value while maintaining an $83.82 consensus target spread.
    Impact
    Ionis Pharmaceuticals shares have experienced severe multiple contraction, shedding over 40% year-to-date as clinical challenges in high-profile programs such as pelacarsen and eplontersen weighed on near-term commercialization forecasts. Despite ongoing quarterly losses, sell-side price targets average $83.82, creating an extreme divergence between prevailing market prices and fundamental platform net present value estimates.
    Affected
    IONSAZN
    Transmission
    Clinical trial setbacks in pelacarsen compress Ionis commercial pipeline enterprise value while maintaining an $83.82 consensus target spread.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    IONSbiotech pipeline valuation compression on phase 3 clinical execution riskMixed1-3mStock dropped >40% YTD on pelacarsen and eplontersen trial setbacks
    AZNpartnered program milestone revenue adjustmentsWatch1-3mAstraZeneca collaborates on joint cardiovascular and rare disease commercialization

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    IONSMixed44.90 2026-09-21+1.89%+1.49%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month